Top View
- Lysosomal Sequestration of Sunitinib: a Novel Mechanism of Drug Resistance
- Effect of Tyrosine Kinase Inhibitors on Renal Handling of Creatinine By
- Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2+ Breast Cancer Cells
- FDA Updates Highlighting the Latest Cancer Treatments
- Evaluation of the KIT/Stem Cell Factor Axis in Renal Tumours
- Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
- Gastrointestinal Stromal Tumors: What Do We Know Now? Christopher L Corless
- Sorafenib and Sunitinib in Renal Cell Carcinoma Mark N
- The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked in Vivo Antitumor Properties and a Favorable Tolerability Profile
- Renal Cell Carcinoma Treatment Regimens
- Sunitinib Malate) Capsules, Oral There Is No Resolution
- Targeted Cancer Therapies Learning Goals Cancer
- Targeting Tyrosine Kinases in Renal Cell Carcinoma: “New Bullets Against Old Guys”
- Sunitinib (Sutent®) (“Su NIT E Nib”)
- Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer ROBIN PARK 1, STEPHEN WILLIAMSON 2, ANUP KASI 2 and ANWAAR SAEED 2
- SUTENT (Sunitinib) RATIONALE for INCLUSION in PA PROGRAM
- Sunitinib Therapy for Melanoma Patients with KIT Mutations
- KIT Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients
- Blocking Autocrine VEGF Signaling by Sunitinib, an Anti-Cancer Drug, Promotes Embryonic Stem Cell Self-Renewal and Somatic Cell
- New Insights Into Molecular Mechanisms of Sunitinib-Associated Side Effects
- Phase I Study of Rapid Alternation Of
- List Item Applications for New Human
- Engineering Stem Cell Factor Ligands with Different C-Kit Agonistic
- When Tyrosine Kinase Inhibitor Sunitinib Can Be Discontinued In
- Transforming Into Oncology- Sunao Manabe President and COO June 2, 2019 ASCO Investor Relations Presentation, Chicago, IL Forward-Looking Statements
- ITD Confer Resistance to Multiple Tyrosine Kinase Inhibitors
- Axitinib, Cabozantinib, Or Everolimus in the Treatment Of
- Tyrosine Kinase Inhibitor Sunitinib Allows Insulin Independence In
- Inhibition of Placental Growth Factor in Renal Cell Carcinoma
- Oral Targeted Therapy for Cancer
- Clinical Trials Appendix Q1 2019 Results Update
- Advances in Targeted Therapy for Esophageal Cancer
- Sutent® (Sunitinib)
- FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions Maria Larrosa-Garcia1 and Maria R
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Emtansine (T-DM1) Resistance in HER2-Positive Cancer
- Imatinib Escalation Or Sunitinib Treatment After First-Line Imatinib in Metastatic Gastrointestinal Stromal Tumor Patients
- Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib
- New Insights Into Molecular Mechanisms of Sunitinib-Associated Side Effects
- Sutent (Sunitinib Malate) Capsules
- Publication Agenda CHMP 07-10 December 2020
- Approval Summary: Sunitinib for Thetreatment of Imatinib Refractory
- Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response
- Update on Molecular Genetics of Gastrointestinal Stromal Tumors
- Correlation of KIT and PDGFRA Mutational Status with Clinical
- Extracellular Domain C-Kit Mutation with Duplication of Ser501ala502
- Mathematical Modeling of the Regulatory T Cell Effects on Renal Cell Carcinoma Treatment
- Evaluation of Drug Therapy Costs for Patients with Breast Cancer, Melanoma and Renal Cell Carcinoma in Moscow in 2016-2017
- Sunitinib: a VEGF and PDGF Receptor Protein Kinase and Angiogenesis Inhibitor
- FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia
- FDA Updates Highlighting the Latest Cancer Treatments
- Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML